子痫
怀孕
阿司匹林
蛋白尿
子痫前期
疾病
胎儿
医学
产科
重症监护医学
胎盘功能不全
血压
儿科
内科学
胎盘
肾
生物
遗传学
作者
Ben W. Mol,Claire T. Roberts,Shakila Thangaratinam,Laura A. Magee,Christianne J.M. de Groot,G Justus Hofmeyr
出处
期刊:The Lancet
[Elsevier]
日期:2015-09-03
卷期号:387 (10022): 999-1011
被引量:1328
标识
DOI:10.1016/s0140-6736(15)00070-7
摘要
Summary
Pre-eclampsia affects 3–5% of pregnancies and is traditionally diagnosed by the combined presentation of high blood pressure and proteinuria. New definitions also include maternal organ dysfunction, such as renal insufficiency, liver involvement, neurological or haematological complications, uteroplacental dysfunction, or fetal growth restriction. When left untreated, pre-eclampsia can be lethal, and in low-resource settings, this disorder is one of the main causes of maternal and child mortality. In the absence of curative treatment, the management of pre-eclampsia involves stabilisation of the mother and fetus, followed by delivery at an optimal time. Although algorithms to predict pre-eclampsia are promising, they have yet to become validated. Simple preventive measures, such as low-dose aspirin, calcium, and diet and lifestyle interventions, show potential but small benefit. Because pre-eclampsia predisposes mothers to cardiovascular disease later in life, pregnancy is also a window for future health. A collaborative approach to discovery and assessment of the available treatments will hasten our understanding of pre-eclampsia and is an effort much needed by the women and babies affected by its complications.
科研通智能强力驱动
Strongly Powered by AbleSci AI